Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
October 24, 2022 16:45 ET | Cingulate Inc.
KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Future Market Insights.png
Rapid progression in Drug Delivery techniques will bolster the Oral Controlled Release Drug Delivery Technology Market to reach US$ 68.4 Bn by 2032 end. Data by Future Market Insights, Inc.
October 17, 2022 06:30 ET | Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The global oral controlled release drug delivery technology market is expected to reach a value of US$ 68.4 Bn in 2032, with sales growing at a healthy...
22157.jpg
Pharmaceutical Drug Delivery Global Market Report 2022: Featuring 3M, AstraZeneca, Pfizer, Bayer, Novartis, Merck & More
September 29, 2022 04:28 ET | Research and Markets
Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The "Pharmaceutical Drug Delivery Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global pharmaceutical drug...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
September 19, 2022 06:45 ET | Cingulate Inc.
Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate’s Precision Timed Release™ (PTR™)...
Cingulate_Logo_400x400_twitter.jpg
Cingulate to Participate in Benzinga All Live Access Event
August 15, 2022 18:34 ET | Cingulate Inc.
KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
lexaria.jpg
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution
August 11, 2022 08:30 ET | Lexaria Bioscience Corp.
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
August 11, 2022 06:45 ET | Cingulate Inc.
$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage...
lexaria.jpg
Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension
August 09, 2022 08:30 ET | Lexaria Bioscience Corp.
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
22157.jpg
Liposomal Drug Delivery Devices Global Market Report 2022: Johnson and Johnson, Novartis & Gilead Sciences Among Key Players Driving 10.3% Annual Growth
August 01, 2022 06:33 ET | Research and Markets
Dublin, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The "Liposomal Drug Delivery Devices Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global liposomal drug...
Cingulate_Logo_400x400_twitter.jpg
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year
July 25, 2022 13:45 ET | Cingulate Inc.
KANSAS CITY, Kan., July 25, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...